Drug intelligence / Profile preview

FOLFOX + lenvatinib + envolizumab

Development stage: Unknown
Lead developer: Centre Léon Bérard
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

A combination therapy consisting of FOLFOX chemotherapy regimen (folinic acid, fluorouracil, and oxaliplatin), lenvatinib, and envolizumab. FOLFOX is a chemotherapy regimen used primarily for colorectal cancer treatment. The drugs in FOLFOX work by destroying rapidly dividing cells such as cancer cells.

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)DNAFGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on FOLFOX + lenvatinib + envolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FOLFOX + lenvatinib + envolizumab.

Explore the full profile